Defence Therapeutics (TSE:DTC)
:DTC
Top Page
Defence Therapeutics
(DTC)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.52
▼(-33.72% Downside)
Action:ReiteratedDate:02/23/26
The score is primarily constrained by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals are mixed with short-term stabilization but longer-term weakness, and valuation provides limited support due to negative earnings and no dividend yield.
Positive Factors
Proprietary Accum™ intracellular delivery platform
Accum™ is a platform technology that improves intracellular delivery and immune activation. As a reusable delivery backbone across ADCs, vaccines and biologics, it provides a structural competitive advantage: one core asset can generate multiple programs, improving optionality and long-term upside if clinical translation succeeds.
Negative Factors
Zero revenue; no commercialization
The company has no product revenue, meaning it remains pre-commercial and dependent on financing to fund operations. This elevates execution risk: successful clinical outcomes and partner deals are required to reach sustainable cash generation, a structural hurdle over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Accum™ intracellular delivery platform
Accum™ is a platform technology that improves intracellular delivery and immune activation. As a reusable delivery backbone across ADCs, vaccines and biologics, it provides a structural competitive advantage: one core asset can generate multiple programs, improving optionality and long-term upside if clinical translation succeeds.
Read all positive factors
Defence Therapeutics (DTC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$33.27M
Dividend YieldN/A
Average Volume (3M)68.27K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth72.92%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding57,369,970
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Defence Therapeutics Business Overview & Revenue Model
Company Description
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision ...
How the Company Makes Money
null...
Defence Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Jun 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -44.73K | -72.34K | -90.92K | -13.82K | 0.00 | 0.00 |
| EBITDA | -3.98M | -3.13M | -12.68M | -6.48M | 0.00 | 0.00 |
| Net Income | -4.33M | -3.52M | -13.19M | -6.76M | -7.34M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 1.37M | 1.65M | 477.75K | 3.53M | 719.67K | 5.61M |
| Cash, Cash Equivalents and Short-Term Investments | 947.35K | 1.23M | 56.55K | 2.79M | 506.70K | 5.45M |
| Total Debt | 1.49M | 1.50M | 1.75M | 1.75M | 0.00 | 0.00 |
| Total Liabilities | 2.59M | 2.91M | 4.06M | 1.97M | 1.11M | 122.26K |
| Stockholders Equity | -1.22M | -1.26M | -3.58M | 1.57M | -387.56K | 5.49M |
Cash Flow | ||||||
| Free Cash Flow | -4.13M | -3.40M | -4.49M | -7.72M | -6.04M | -2.29M |
| Operating Cash Flow | -4.94M | -3.40M | -4.29M | -7.66M | -6.04M | -2.29M |
| Investing Cash Flow | -30.05K | 3.60K | -203.24K | -65.80K | 0.00 | 0.00 |
| Financing Cash Flow | 5.79M | 4.57M | 1.76M | 10.01M | 1.10M | 5.88M |
Defence Therapeutics Technical Analysis
Negative
0.78
Price Trends
0.61
Negative
0.70
Negative
0.71
Negative
Market Momentum
-0.01
Positive
36.78
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DTC, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.61, and above the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DTC.
Defence Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$5.79M | -0.15 | 123.88% | ― | ― | 90.81% | |
46 Neutral | C$40.46M | -0.41 | -205.87% | ― | ― | 62.01% | |
45 Neutral | C$33.27M | -6.55 | ― | ― | ― | 72.92% | |
42 Neutral | C$42.61M | -4.40 | -103.51% | ― | ― | 54.74% | |
| ― | C$2.62M | -1.60 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:DTC
Defence Therapeutics
0.58
-0.50
-46.30%
TSE:APS
Aptose Biosciences
2.27
-2.71
-54.42%
TSE:MDNA
Medicenna Therapeutics Corp
0.62
-0.38
-38.00%
TSE:BCT
BriaCell Therapeutics
5.58
-52.32
-90.36%
TSE:BIOV
BioVaxys Technology
0.09
-0.41
-82.00%
TSE:ONCO
Onco-Innovations Ltd.
1.47
-0.19
-11.45%
Defence Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Defence Therapeutics Eases Terms on 800,000 Warrants to Boost Investor Uptake
Positive
Mar 21, 2026
Defence Therapeutics has amended the terms of 800,000 common share purchase warrants originally issued in a 2024 private placement, extending their expiry dates by 12 months and reducing the exercise price from $1.00 to $0.75 per share. None of th...
Business Operations and StrategyPrivate Placements and Financing
Defence Therapeutics Raises $9.6 Million in Private Placement to Advance Oncology Programs
Positive
Mar 9, 2026
Defence Therapeutics has closed a private placement of 17,445,455 units at $0.55 per unit, raising gross proceeds of approximately $9.6 million. Each unit consists of one common share and one warrant exercisable at $0.65 for 24 months, with instit...
Business Operations and Strategy
Defence Therapeutics Targets Global Partnerships as It Showcases Accum Platform at March Industry Events
Positive
Mar 2, 2026
Defence Therapeutics will showcase its Accum platform at several major industry events in March 2026, including BIO-Europe Spring in Lisbon and DCAT Week in New York, to pursue strategic partnerships and strengthen its biomanufacturing capabilitie...
Business Operations and StrategyPrivate Placements and Financing
Defence Therapeutics Seeks Up to $11 Million in Structured Private Placement
Positive
Feb 28, 2026
Defence Therapeutics has launched a private placement of up to 20,000,000 units at $0.55 each, for gross proceeds of up to $11 million, with each unit comprising one common share and one warrant exercisable at $0.65 for 24 months. The company has ...
Business Operations and Strategy
Defence Therapeutics Refines Accum ADC Strategy with Expert Advisory Board
Positive
Feb 10, 2026
Defence Therapeutics has convened its Scientific Advisory Board to refine the strategic development of its Accum® platform for antibody-drug conjugate applications. The meeting brought together experts in ADC chemistry, translational science,...
Business Operations and StrategyExecutive/Board Changes
Defence Therapeutics Refines Accum ADC Strategy With New Scientific Advisory Board
Positive
Feb 10, 2026
Defence Therapeutics has convened a multidisciplinary Scientific Advisory Board to refine the strategic development of its Accum® platform for antibody-drug conjugate applications, emphasizing improved intracellular delivery of ADC payloads. ...
Business Operations and Strategy
Defence Therapeutics to Spotlight Accum Platform at World ADC Europe 2026
Positive
Feb 4, 2026
Defence Therapeutics will present its Accum platform at World ADC Europe 2026 in London, positioning the technology as a means to enhance intracellular delivery for antibody-drug conjugates and advanced oncology biologics. By engaging prospective ...
Business Operations and StrategyProduct-Related Announcements
Defence Therapeutics Deepens CNL Partnership to Fast-Track Radiopharmaceutical Pipeline
Positive
Jan 28, 2026
Defence Therapeutics has expanded its long-standing collaboration with Canadian Nuclear Laboratories to accelerate development of its Accum®-enhanced radiopharmaceutical pipeline. Building on progress in a lead radio-immunoconjugate program t...
Business Operations and Strategy
Defence Therapeutics Refines Strategy Around Accum® Precision Drug-Delivery Platform
Positive
Jan 21, 2026
Defence Therapeutics has refined its corporate positioning to emphasize its role as a precision intracellular drug-delivery specialist centered on its proprietary Accum® platform. By improving cellular uptake and payload release, Accum® ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.